Alliqua (ALQA) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Alliqua BioMedical, Inc. Reports Second Quarter Financial Results
August 6, 2015 7:05 AM EDTLANGHORNE, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the second quarter ended June 30, 2015.
Q2 Highlights:
Total revenue increased 202% year-over-year to $3.1 million. Organic revenue growth was approximately 99% year-over-year. Products revenue increased 383% year-over-year to $2.7 million, of which organic product revenue growth was 188% year-over-year. Gross margin was 56.2% compared to 19.3% last year and 42.9% in the first quarter of 2015. On April 16th, Alliqua announced that the Company's Biovance® Human Amniotic Membrane Allograft received... MoreAlliqua BioMedical, Inc. Reports Second Quarter Financial Results
August 6, 2015 7:05 AM EDTLANGHORNE, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the second quarter ended June 30, 2015.
Q2 Highlights:
Total revenue increased 202% year-over-year to $3.1 million. Organic revenue growth was approximately 99% year-over-year. Products revenue increased 383% year-over-year to $2.7 million, of which organic product revenue growth was 188% year-over-year. Gross margin was 56.2% compared to 19.3% last year and 42.9% in the first quarter of 2015. On April 16th, Alliqua announced that the Company's Biovance® Human Amniotic Membrane Allograft received... More